<DOC>
	<DOCNO>NCT00793975</DOCNO>
	<brief_summary>The purpose study determine IMC-1121B safe patient , determine best dose IMC-1121B give patient .</brief_summary>
	<brief_title>Study IMC-1121B Patients With Tumors That Have Not Responded Therapy</brief_title>
	<detailed_description>The purpose study establish safety profile maximum tolerate dose ( MTD ) anti-VEGFR-2 monoclonal antibody IMC-1121B administer weekly patient advance solid tumor respond standard therapy standard therapy available .</detailed_description>
	<mesh_term>Endothelial Growth Factors</mesh_term>
	<mesh_term>Ramucirumab</mesh_term>
	<criteria>Histopathologicallydocumented , measurable evaluable ( nonmeasurable ) , advance primary recurrent solid tumor respond standard therapy standard therapy available . ECOG performance status score ≤ 2 study entry Able provide write informed consent A life expectancy &gt; 3 month Adequate hematologic function , define : ANC ≥ 1500/mm^3 , hemoglobin level ≥ 10 gm/dL , platelet count ≥ 100,000/mm^3 Adequate hepatic function , define : total bilirubin level ≤ 1.5 x ULN , AST ALT level ≤ 2.5 x ULN ≤ 5 x ULN know liver metastasis Adequate renal function , define serum creatinine level ≤ 1.5 x ULN Use effective contraception ( per institutional standard ) , procreative potential exists Adequate recovery recent surgery , chemotherapy , radiation therapy . At least 28 day must elapse major surgery , prior chemotherapy , prior treatment investigational agent device , prior radiation therapy ( palliative radiation therapy allow ) . Accessible treatment followup . Patients enrol trial must treat participate center . Patients large centrallylocated pulmonary lesion adjacent invade large blood vessel . Patients chemotherapy therapeutic radiotherapy within 28 day ( 6 week nitrosoureas mitomycin C ) prior enter study patient ongoing side effect ≥ grade 2 due agent administer 28 day earlier . Prior leave chest wall radiotherapy cumulative anthracycline dose ≥ 300mg/m2 ( ejection fraction within normal institutional limit , patient enrol ) . Any concurrent malignancy nonmelanomatous skin cancer carcinoma situ cervix . Patients previous malignancy without evidence disease ≥ 3 year allow enter trial . Uncontrolled intercurrent illness include , limited : ongoing active infection require parenteral antibiotic , symptomatic congestive heart failure , unstable angina pectoris , angioplasty , stenting , myocardial infarction within 6 month , uncontrolled hypertension , clinically significant cardiac arrhythmia , uncontrolled diabetes , psychiatric illness/social situation would compromise patient safety limit compliance study requirement , patient symptomatic brain metastases A serious nonhealing active wound , ulcer , bone fracture Known HIV positivity A major surgical procedure , open biopsy , significant injury within 28 day prior treatment Current recent use ( within 28 day ) thrombolytic agent Current recent use ( within 28 day ) fulldose warfarin Chronic daily treatment aspirin ( &gt; 325 mg/day ) nonsteroidal antiinflammatory medication know inhibit platelet function History clinical evidence deep venous arterial thrombosis ( include pulmonary embolism ) within 6 month prior study entry Proteinuria ≥1+ routine urinalysis ( patient protein value ≤ 500mg confirm 24hour urine collection eligible ) Pregnant ( confirm serum beta human chorionic gonadotropin [ βHCG ] ) breast feed Prior treatment bevacizumab agent specifically target VEGF ligand receptor within 6 week study entry Monoclonal antibody within 6 week study entry Positive antiIMC1121B antibody response History allergic reaction monoclonal antibody therapeutic protein Employees investigator study center direct involvement study study direction investigator study center , well family member employee .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Tumors</keyword>
	<keyword>Antibodies , Monoclonal</keyword>
</DOC>